Isolation of HIV antibodies advances search for AIDS vaccine

A team of researchers has "identified 17 potent antibodies whose discovery opened up valuable pathways in the search for an AIDS vaccine," Agence France-Presse reports (8/17). The researchers "at and associated with the International AIDS Vaccine Initiative (IAVI), the Scripps Research Institute, the biotechnology company Theraclone Sciences and Monogram Biosciences Inc., a LabCorp company, report in the current issue of Nature" that the antibodies are "capable of neutralizing a broad spectrum of variants of HIV, the virus that causes AIDS," according to a joint press release (8/17).

IAVI "said the quest for HIV-neutralizing antibodies was 'perhaps the greatest challenge' facing vaccine engineers," AFP writes (8/17). Wayne Koff, chief scientific officer for IAVI, "said the problem with HIV is that it's a hyper-variable virus," meaning that the virus, which "has millions of strains," is "different all over the world," making broadly neutralizing antibodies necessary for a vaccine that will work worldwide, VOA News reports (DeCapua, 8/17).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New nasal vaccine could help stop the spread of whooping cough